Istradefylline Versus Opicapone for "Off" Episodes in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Alok SinghDhyuti GuptaSuryaprakash DhaneriaPranav G ShethPublished in: Annals of neurosciences (2021)
Both drugs were comparable in efficacy; however, istradefylline seemed to be better in reducing the UPDRS III score. Although the incidence of TEAEs and dyskinesia were higher with both the drugs, the incidence of dyskinesia was more in the opicapone group.
Keyphrases